Monthly Archives: July 2018

Genprex Enters Agreement with the University of Texas MD Anderson Cancer Center to Study Oncoprex in Combination with Immunotherapies

New study will evaluate synergistic effect of Oncoprex gene therapy on checkpoint inhibition.

Study may identify biomarkers that can predict the response to therapy across different cancers

Read More

Genprex To Present At The Singular Research Summer Solstice 2018 Conference

NEW YORK, July 18, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that Rodney Varner, Chairman and Chief Executive Officer, will present

Read More

 
STAY IN THE KNOW WITH
EMAIL NEWS ALERTS
 
Don't miss out. Get our news delivered to your inbox.
 

 
close-link
 
Get Email News Alerts
 
close-link